- Home
- GORV vs INAB Comparison
GORV vs INAB Comparison
Compare GORV & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- INAB
- Stock Information
- Founded
- GORV 1976
- INAB 2016
- Country
- GORV United States
- INAB United States
- Employees
- GORV N/A
- INAB N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- INAB Health Care
- Exchange
- GORV Nasdaq
- INAB Nasdaq
- Market Cap
- GORV 30.7M
- INAB 30.8M
- IPO Year
- GORV 2015
- INAB 2021
- Fundamental
- Price
- GORV $1.50
- INAB $0.30
- Analyst Decision
- GORV Hold
- INAB Strong Buy
- Analyst Count
- GORV 2
- INAB 3
- Target Price
- GORV $2.00
- INAB $10.00
- AVG Volume (30 Days)
- GORV 43.4K
- INAB 432.1K
- Earning Date
- GORV 11-01-2024
- INAB 08-08-2024
- Dividend Yield
- GORV N/A
- INAB N/A
- EPS Growth
- GORV N/A
- INAB N/A
- EPS
- GORV N/A
- INAB N/A
- Revenue
- GORV $987,991,000.00
- INAB N/A
- Revenue This Year
- GORV N/A
- INAB N/A
- Revenue Next Year
- GORV $8.00
- INAB N/A
- P/E Ratio
- GORV N/A
- INAB N/A
- Revenue Growth
- GORV N/A
- INAB N/A
- 52 Week Low
- GORV $1.49
- INAB $0.30
- 52 Week High
- GORV $10.78
- INAB $2.48
- Technical
- Relative Strength Index (RSI)
- GORV 26.60
- INAB 20.37
- Support Level
- GORV $1.62
- INAB $0.50
- Resistance Level
- GORV $1.80
- INAB $0.56
- Average True Range (ATR)
- GORV 0.16
- INAB 0.06
- MACD
- GORV -0.01
- INAB -0.01
- Stochastic Oscillator
- GORV 1.25
- INAB 0.77
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.